GeneDx Holdings Corp. reported significant financial growth in its latest 10-Q filing for the quarter ending September 30, 2025. The company achieved total revenue of $116.7 million, a 52% increase from $76.9 million in the same period last year. Diagnostic test revenue alone rose by 47% to $113.5 million, driven by a 33% increase in test volumes and improved reimbursement rates for whole exome and genome sequencing. The company also noted a substantial increase in gross profit, which reached $84.5 million, up 77% from $47.8 million a year earlier.
In terms of operational metrics, GeneDx reported a total of 25,702 exome and genome tests resulted during the quarter, representing 43% of all test results, compared to 19,262 tests, or 33%, in the prior year. The company’s customer base continues to expand, with increased engagement in its genomic testing services. The acquisition of Fabric Genomics, completed in May 2025, contributed $2.0 million in revenue during the quarter, reflecting the strategic move to enhance its service offerings in AI-based genomic analysis.
Despite the revenue growth, GeneDx reported a net loss of $7.6 million for the quarter, a slight improvement from a loss of $8.3 million in the same period last year. The company’s operating expenses also increased, with research and development costs rising by 70% to $19.8 million, and general and administrative expenses increasing by 65% to $44.4 million. These increases were attributed to higher compensation costs and expenses related to the integration of Fabric Genomics.
Looking ahead, GeneDx maintains a positive outlook, bolstered by its strong cash position of $96.0 million as of September 30, 2025, which includes cash and cash equivalents. The company believes this liquidity will support its operations and growth initiatives for at least the next twelve months. Additionally, GeneDx is focused on expanding its market presence and enhancing its product offerings, particularly in the realm of genomic diagnostics, as it continues to navigate the evolving regulatory landscape surrounding laboratory-developed tests.
About GeneDx Holdings Corp.
GeneDx Holdings specializes in genetic testing and genomic interpretation for rare and complex diseases. Utilizing exome and whole genome sequencing, the company provides diagnostic solutions, data analysis, and interpretation services to healthcare providers, researchers, and biopharma partners. Its industry-leading dataset and advanced bioinformatics enable accurate, scalable, and actionable genetic insights, primarily serving pediatric and rare disease markets worldwide.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.